PODD earnings / call / takeaways

PODD Q3 FY26 earnings call: key takeaways

What PODD said on its earnings call of November 4, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 4, 2026·AI-generated from the call transcript and Lician data

Insulet reported revenue of $842 million for Q3 2026, exceeding the consensus revenue estimate of $832.6 million (2:17)
EPS of $1.99 beat the consensus estimate of $1.59 (20:59)
The company narrowed its full-year revenue guidance to the top end of its prior range and provided an updated outlook for 2027, indicating a more conservative approach due to increased competition and market dynamics. (5:43)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	$1.59	–	–
Revenue	$832.6M	–	–

What changed since last quarter

Insulet narrowed its full-year revenue guidance to the top end of its prior range, reflecting strong Q3 performance and momentum into Q4. (5:43)
The company provided an updated 2027 outlook, indicating a more conservative approach due to increased competition and market dynamics, with growth expected to moderate from the mid-teens framework. (28:59)
Insulet announced a $1 billion increase in its share repurchase authorization, with $400 million allocated for Q4, reflecting confidence in the Omnipod platform and future growth. (5:43)

Guidance

Metric	This call	Previous call
Revenue	Full-year 2026 revenue growth of 21-22% on a constant currency basis. (24:59)	not captured
Other	2027 total company growth expected to be modestly below mid-teens. (28:59)	not captured

What analysts pressed on

Whether tariffs will pressure gross margin next year. (52:56)
How the new competitors will impact market share and growth in 2027. (40:59)
The potential impact of changes in sampling programs on new customer starts. (48:43)

In their words

We are pleased with our progress in the quarter, and I want to take a step back and provide some broader perspective. Ashley (2:17)
We saw stronger retention, increased time and range, and three-quarters of our users reported feeling more confident managing their diabetes. (9:29)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.